Development of in House ELISAs to Detect Antibodies to SARS-CoV-2 in Infected and Vaccinated Humans by Using Recombinant S, S1 and RBD Proteins.
Development of in House ELISAs to Detect Antibodies to SARS-CoV-2 in Infected and Vaccinated Humans by Using Recombinant S, S1 and RBD Proteins.
复制标题
DOI：
10.3390/diagnostics12123085
复制
发表时间：
2022-12-07
期刊：
影响因子：
3.6
通讯作者：
Yilmaz, Huseyin
中科院分区：
文献类型：
--
作者：
Yilmaz, Aysun;Turan, Nuri;Kocazeybek, Bekir Sami;Dinc, Harika Oyku;Tali, Hasan Emre;Aydin, Ozge;Tali, Hamid Besim;Yilmaz, Semaha Gul;Konukoglu, Dildar;Borekci, Sermin;Bold, Dashzeveg;Sosa, Gleyder Roman;Gungordu, Nejdiye;Vardaloglu, Ilgim;Gareayaghi, Nesrin;Guzel, Mine;Guner, Ebru;Sadeyen, Jean-Remy;Chang, Pengxiang;Iqbal, Munir;Richt, Juergen A.;Yilmaz, Huseyin
(1) Background: The aim of this study was to produce in-house ELISAs which can be used to determine SARS-CoV-2-specific antibody levels directed against the spike protein (S), the S1 subunit of S and the receptor binding domain (RBD) of S in SARS-CoV-2 vaccinated and infected humans. (2) Methods: Three in-house ELISAs were developed by using recombinant proteins of SARS-CoV-2, namely the S, S1 and RBD proteins. Specificity and sensitivity evaluations of these tests were performed using sera from SARS-CoV-2-infected (n = 70) and SARS-CoV-2-vaccinated (n = 222; CoronaVac vaccine) humans in Istanbul, Turkey. The analyses for the presence of SARS-CoV-2-specific antibodies were performed using the in-house ELISAs, a commercial ELISA (Abbott) and a commercial surrogate virus neutralization test (sVNT). We also analyzed archival human sera (n = 50) collected before the emergence of COVID-19 cases in Turkey. (3) Results: The sensitivity of the in-house S, S1 and RBD ELISAs was found to be 88.44, 90.17 and 95.38%, while the specificity was 72.27, 89.08 and 89.92%, respectively, when compared to the commercial SARS-CoV-2 antibody test kit. The area under curve (AUC) values were 0.777 for the in-house S ELISA, 0.926 for the S1 ELISA, and 0.959 for the RBD ELISA. The kappa values were 0.62, 0.79 and 0.86 for the S, S1 and RBD ELISAs, respectively. (4) Conclusions: The in-house S1 and RBD ELISAs developed in this study have acceptable performance characteristics in terms of sensitivity, specificity, AUC and kappa values. In particular, the RBD ELISA seems viable to determine SARS-CoV-2-specific antibody levels, both in infected and vaccinated people, and help mitigate SARS-CoV-2 outbreaks and spread.
登录
查看更多内容
五个可获得五种可获得SARS-COV-2抗体并鉴定具有高中和滴度的个体的抗体的比较性能。
影响因子：
9.4
作者：
Patel EU;Bloch EM;Clarke W;Hsieh YH;Boon D;Eby Y;Fernandez RE;Baker OR;Keruly M;Kirby CS;Klock E;Littlefield K;Miller J;Schmidt HA;Sullivan P;Piwowar-Manning E;Shrestha R;Redd AD;Rothman RE;Sullivan D;Shoham S;Casadevall A;Quinn TC;Pekosz A;Tobian AAR;Laeyendecker O
通讯作者：
Laeyendecker O
影响因子：
13.2
作者：
Sun, Baoqing;Feng, Ying;Chen, Ling
通讯作者：
Chen, Ling
影响因子：
32.4
作者：
Ni, Ling;Ye, Fang;Dong, Chen
通讯作者：
Dong, Chen
影响因子：
20.6
作者：
Tang, Xiaolu;Wu, Changcheng;Lu, Jian
通讯作者：
Lu, Jian
影响因子：
5.4
作者：
Telenti, Amalio;Hodcroft, Emma B.;Robertson, David L.
通讯作者：
Robertson, David L.